Victoria A. Vardell

Victoria A. Vardell

Auto-generated profile, based on publicly available information

Victoria A. Vardell

Department of Internal Medicine, University of Utah, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
STSrinivas Tantravahi
Srinivas Tantravahi
BHBenjamin Haaland
Benjamin Haaland
BMBrian McClune
Brian McClune
DSDouglas Weston Sborov
Douglas Weston Sborov

19 January 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
LFLindsey Fitzgerald
Lindsey Fitzgerald
HSHarsh Shah
Harsh Shah
BHBoyu Hu
Boyu Hu
DSDeborah M. Stephens
Deborah M. Stephens

20 April 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
LFLindsey A. Fitzgerald
Lindsey A. Fitzgerald
HSHarsh R. Shah
Harsh R. Shah
BHBoyu Hu
Boyu Hu
DSDeborah M. Stephens
Deborah M. Stephens

31 July 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
JOJennifer Ose
Jennifer Ose
ARAnton Rets
Anton Rets
STSrinivas K. Tantravahi
Srinivas K. Tantravahi
APAmi B. Patel
Ami B. Patel

10 October 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
DEDaniel A. Ermann
Daniel A. Ermann
VVVictoria A. Vardell
Victoria A. Vardell
HSHarsh Shah
Harsh Shah
LFLindsey Fitzgerald
Lindsey Fitzgerald
RTRanda Tao
Randa Tao
BHBoyu Hu
Boyu Hu

22 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
VVVictoria Vardell
Victoria Vardell
DEDaniel Ermann
Daniel Ermann
LFLindsey Fitzgerald
Lindsey Fitzgerald
HSHarsh Shah
Harsh Shah
BHBoyu Hu
Boyu Hu
DSDeborah Stephens
Deborah Stephens
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, with the highest incidence in the White, non-Hispanic population. To better understand underrepresented minority CLL patients, patients diagnosed with CLL from 2004-2018 were identified in the National Cancer Database. Of 97 804 CLL patients, 90.7% of patients were White, 7.6% Black. Compared to White patients, Black patients were younger (median age 66 years vs. 70 years), more likely to have ≥1 comorbidity (27.9% vs. 21.3%), more likely to receive CLL-directed therapy at diagnosis (35.9% vs 23.6%; p<0.001), and had a shorter median OS of 7.0 years (95% CI 6.7-7.3) compared to White patients (9.1 years [95% CI 9.0-9.3]), p<0.001). On multivariate analysis, Black race was independently associated with shorter OS (HR 1.51 [95% CI 1.46-1.57], p<0.001), which was also demonstrated in a propensity score matched sample (matched by age, comorbidity, and socioeconomic features), where Black patients had shorter OS compared to White patients (HR 1.30 [95% CI 1.23-1.37, p<0.001]). In the largest study to date describing minority CLL patients, we found significantly reduced survival in Black CLL patients, highlighting the need for targeted efforts to provide equitable outcomes.